PE20211199A1 - USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY - Google Patents
USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSYInfo
- Publication number
- PE20211199A1 PE20211199A1 PE2021000514A PE2021000514A PE20211199A1 PE 20211199 A1 PE20211199 A1 PE 20211199A1 PE 2021000514 A PE2021000514 A PE 2021000514A PE 2021000514 A PE2021000514 A PE 2021000514A PE 20211199 A1 PE20211199 A1 PE 20211199A1
- Authority
- PE
- Peru
- Prior art keywords
- reboxetin
- narcolepsy
- treatment
- refers
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UN KIT QUE COMPRENDE UNA COMPOSICION FARMACEUTICA QUE COMPRENDE REBOXETINA EN UNA CANTIDAD DE 10 MG E INSTRUCCIONES DE USO DE LA COMPOSICION FARMACEUTICA. TAMBIEN SE REFIERE AL USO DE REBOXETINA PARA EL TRATAMIENTO DE LA NARCOLEPSIA CON CATAPLEXIA, QUE COMPRENDE ADMINISTRAR REBOXETINA A UN HUMANO QUE LO NECESITA, EN DONDE LA REBOXETINA SE ADMINISTRA AL MENOS UNA VEZ AL DIA DURANTE AL MENOS TRES SEMANAS.REFERS TO A KIT INCLUDING A PHARMACEUTICAL COMPOSITION INCLUDING REBOXETIN IN A QUANTITY OF 10 MG AND INSTRUCTIONS FOR USE OF THE PHARMACEUTICAL COMPOSITION. IT ALSO REFERS TO THE USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY WITH CATAPLEXIA, WHICH INCLUDES ADMINISTERING REBOXETIN TO A HUMAN IN NEED OF IT, WHERE REBOXETIN IS ADMINISTERED AT LEAST ONCE A DAY FOR AT LEAST THREE.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862745956P | 2018-10-15 | 2018-10-15 | |
| PCT/US2019/056134 WO2020081461A1 (en) | 2018-10-15 | 2019-10-14 | Use of reboxetine to treat narcolepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211199A1 true PE20211199A1 (en) | 2021-07-01 |
Family
ID=70284075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000514A PE20211199A1 (en) | 2018-10-15 | 2019-10-14 | USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3866768A4 (en) |
| JP (2) | JP2022504975A (en) |
| KR (2) | KR20210071046A (en) |
| CN (1) | CN112888430A (en) |
| AU (3) | AU2019361915A1 (en) |
| BR (1) | BR112021007019A2 (en) |
| CA (1) | CA3115983A1 (en) |
| CL (1) | CL2021000924A1 (en) |
| CO (1) | CO2021004681A2 (en) |
| CR (1) | CR20210514A (en) |
| EC (1) | ECSP21031200A (en) |
| IL (2) | IL282311B2 (en) |
| MX (2) | MX2021004207A (en) |
| PE (1) | PE20211199A1 (en) |
| SG (1) | SG11202103588WA (en) |
| WO (1) | WO2020081461A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20190381056A1 (en) | 2018-06-17 | 2019-12-19 | Axsome Therapeutics, Inc. | Compositions for delivery of reboxetine |
| WO2021113163A1 (en) * | 2019-12-03 | 2021-06-10 | Axsome Therapeutics, Inc. | Use of reboxetine to treat nervous system disorders |
| US20200147093A1 (en) | 2018-10-15 | 2020-05-14 | Axsome Therapeutics, Inc. | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
| US11020402B2 (en) | 2018-10-15 | 2021-06-01 | Axsome Therapeutics, Inc. | Use of reboxetine to treat narcolepsy |
| WO2023068747A1 (en) * | 2021-10-19 | 2023-04-27 | 단국대학교 천안캠퍼스 산학협력단 | Composition comprising reboxetine as active ingredient for prevention or treatment of sarcopenia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6485746B1 (en) * | 2000-08-25 | 2002-11-26 | Neurocrine Biosciences, Inc. | Controlled-release sedative-hypnotic compositions and methods related thereto |
| EP1763354A2 (en) * | 2004-06-09 | 2007-03-21 | Pfizer Limited | Use of reboxetine for the treatment of pain |
| BR112015022197B1 (en) * | 2013-03-13 | 2022-06-07 | Sk Biopharmaceuticals Co., Ltd. | Use of a compound for the treatment of cataplexy |
-
2019
- 2019-10-14 WO PCT/US2019/056134 patent/WO2020081461A1/en not_active Ceased
- 2019-10-14 CN CN201980067756.9A patent/CN112888430A/en active Pending
- 2019-10-14 IL IL282311A patent/IL282311B2/en unknown
- 2019-10-14 KR KR1020217013455A patent/KR20210071046A/en not_active Ceased
- 2019-10-14 AU AU2019361915A patent/AU2019361915A1/en not_active Abandoned
- 2019-10-14 CA CA3115983A patent/CA3115983A1/en active Pending
- 2019-10-14 CR CR20210514A patent/CR20210514A/en unknown
- 2019-10-14 BR BR112021007019-2A patent/BR112021007019A2/en unknown
- 2019-10-14 JP JP2021520615A patent/JP2022504975A/en active Pending
- 2019-10-14 KR KR1020247025741A patent/KR20240119194A/en active Pending
- 2019-10-14 EP EP19874099.5A patent/EP3866768A4/en active Pending
- 2019-10-14 SG SG11202103588WA patent/SG11202103588WA/en unknown
- 2019-10-14 PE PE2021000514A patent/PE20211199A1/en unknown
- 2019-10-14 MX MX2021004207A patent/MX2021004207A/en unknown
- 2019-10-14 IL IL319177A patent/IL319177A/en unknown
-
2021
- 2021-04-12 MX MX2025003477A patent/MX2025003477A/en unknown
- 2021-04-14 CL CL2021000924A patent/CL2021000924A1/en unknown
- 2021-04-14 CO CONC2021/0004681A patent/CO2021004681A2/en unknown
- 2021-04-30 EC ECSENADI202131200A patent/ECSP21031200A/en unknown
-
2023
- 2023-02-16 AU AU2023200917A patent/AU2023200917A1/en not_active Abandoned
-
2025
- 2025-02-23 AU AU2025201286A patent/AU2025201286A1/en active Pending
- 2025-06-10 JP JP2025096479A patent/JP2025134749A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240119194A (en) | 2024-08-06 |
| ECSP21031200A (en) | 2021-05-31 |
| AU2023200917A1 (en) | 2023-03-23 |
| MX2021004207A (en) | 2021-08-11 |
| BR112021007019A2 (en) | 2021-07-13 |
| CL2021000924A1 (en) | 2021-09-03 |
| CA3115983A1 (en) | 2020-04-23 |
| SG11202103588WA (en) | 2021-05-28 |
| IL282311B1 (en) | 2025-04-01 |
| IL282311A (en) | 2021-05-31 |
| CR20210514A (en) | 2021-11-12 |
| WO2020081461A1 (en) | 2020-04-23 |
| CN112888430A (en) | 2021-06-01 |
| AU2019361915A1 (en) | 2021-05-13 |
| IL282311B2 (en) | 2025-08-01 |
| EP3866768A4 (en) | 2022-01-05 |
| JP2022504975A (en) | 2022-01-13 |
| AU2025201286A1 (en) | 2025-03-13 |
| CO2021004681A2 (en) | 2021-06-21 |
| MX2025003477A (en) | 2025-05-02 |
| NZ775057A (en) | 2024-09-27 |
| JP2025134749A (en) | 2025-09-17 |
| IL319177A (en) | 2025-04-01 |
| KR20210071046A (en) | 2021-06-15 |
| EP3866768A1 (en) | 2021-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211199A1 (en) | USE OF REBOXETIN FOR THE TREATMENT OF NARCOLEPSY | |
| CO2021000174A2 (en) | Topical compositions for pain relief | |
| CY1123398T1 (en) | COMBINATION COMPOSITION | |
| AR096892A1 (en) | A PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF MELANOMA | |
| BR112015026247A8 (en) | compound in combination with a cytidine analogue, pharmaceutical composition comprising them, use thereof and kit | |
| CL2019002218A1 (en) | Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease. | |
| AR103118A1 (en) | ANAMORELINE-BASED MEDICAL TREATMENTS | |
| PE20181332A1 (en) | METHODS OF SEDATION AND PARENTERAL FORMULATION FOR USE DURING THE TREATMENT OF CRITICAL CARE | |
| AR111374A1 (en) | USE OF LIK066 IN PATIENTS WITH HEART FAILURE | |
| MX2020007760A (en) | Compositions and methods of enhancing 5-hydroxytryptophan bioavailability. | |
| ES2525009T3 (en) | Glycoproteins that have lipid mobilization properties and therapeutic uses thereof | |
| AR065139A1 (en) | MEDICATION FOR THE TREATMENT OF ENDOMETRIOSIS | |
| AR048806A1 (en) | USE OF CARIOFILENES IN THE PREPARATION OF MEDICINES AND TREATMENT OF BODY INFLAMMATION AND INFLAMMATORY PAIN AFFECTIONS | |
| CL2022001079A1 (en) | Methods and compositions for the treatment of rett syndrome | |
| CL2008001477A1 (en) | Pharmaceutical composition composed of the synergistic combination of an anticonvulsant agent such as gabapentin and a non-steroidal anti-inflammatory agent such as meloxicam, the concentration ranges present for gabapentin are 3 to 300 mg and 0.1 to 30 mg for meloxicam; and use to treat neuropathic pain | |
| AR047154A1 (en) | TREATMENT OF INSOMNIA IN HUMAN PATIENTS ADMINISTRANDOLES A DAILY AMOUNT OF GABOXADOL | |
| AR061046A1 (en) | MIRTAZAPINE FOR THE TREATMENT OF NEUROPATHIC PAIN | |
| PE20210370A1 (en) | METHODS TO MODULATE PLASMA LEVELS OF TETRABENAZINE METABOLITES USING BUPROPION | |
| MX2016006375A (en) | A combination of dosage units for use in the treatment of pre-term labour condition. | |
| MX2020000702A (en) | Non-pulsatile prolonged-release betahistine oral solid compositions. | |
| PL426950A1 (en) | Pharmaceutical composition and set of compositions, device for administration of the set of pharmaceutical compositions, method of administration of the set of compositions and use in regeneration of the locomotor system | |
| AR048068A1 (en) | PIPERAZINAS DERIVED FROM UREA FOR THE TREATMENT OF ENDOMETRIOSIS | |
| BRPI0509305A (en) | use of an insulin sensitizer, pharmaceutical composition, and kit | |
| EA202190269A1 (en) | PHARMACEUTICAL COMPOSITION IN THE FORM OF A CHEWING TABLET OF DIOSMINE OR FLAVONOID FRACTION | |
| CL2022001476A1 (en) | Use of reboxetine to treat disorders of the nervous system |